Aktana provides an AI-enabled decision-support platform that uses embedded AI and machine learning, refined by real-time human insight, to help life sciences commercial teams anticipate customer needs and coordinate multichannel engagement. Its platform enables personalized, channel-coordinated interactions between commercial teams and healthcare providers to drive better engagement and patient care. Aktana supports more than 100 brands worldwide and counts more than half of the world's top-20 pharmaceutical companies as customers. The company reports customer sales lift of up to 15% from its framework for intelligent engagement. Aktana is headquartered in San Francisco and maintains offices in Philadelphia, London, Barcelona, Tokyo, Osaka, Shanghai, Beijing, Sydney, and Sao Paulo. It is backed by HLM Venture Partners, Leerink Partners, SafeGuard Ventures, and Starfish Ventures. Aktana provides a decision support platform that delivers data-driven insights and suggestions directly to sales reps and coordinates multi-channel actions for global life sciences companies. Its decision support engine examines market data and cross-channel activity, identifies best actions, learns what works best, and delivers recommendations into reps' and marketing teams' CRM workflows. Founded in 2011 and led by CEO David Ehrlich, the company is based in San Francisco and also has offices in New York, Tokyo and San Diego. Aktana raised $17.5m in funding in a round led by Safeguard Scientifics, which will initially deploy up to $8.25m, with participation from existing investor Starfish Ventures and others. The company intends to use the funds to continue product development and for international expansion, with plans to open offices in China and Europe.

Total raised

$38M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Sep 2019